Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Femtosecond Lasers: Expanding The Premium Cataract Surgery Market

Laser Cataract User Survey Shows Strong Initial Uptake

Executive Summary

When femtosecond lasers for cataract surgery hit the market in early 2011, it was apparent that that they would bring unprecedented precision to the procedure. The key questions surrounding this emerging field quickly shifted to commercial viability: how would US cataract surgeons and facilities be able to pay for this expensive new technology in a procedure that is reimbursed almost entirely by Medicare, and therefore subject to strict billing limitations? A survey of early laser adopters in the US, detailed below, suggests that surgeons are successfully navigating these regulatory hurdles and incorporating the new lasers into their practices.

Advertisement

Related Content

Toward Spectacle-Free Cataract Surgery
Laser Cataract Surgery: Sorting Out The Business Case

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT035551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel